Cannabidivarin (CBDV) Versus Placebo in Children with Autism Spectrum Disorder
Abstract
The CDC currently estimates 1 in 36 children have Autism Spectrum Disorder (ASD). Children with ASD have problems with social communication, irritability, repetitive behaviors, impulsivity, temper tantrums, and cause high caregiver burden. The only medications approved by the FDA for symptoms of ASD are aripiprazole and risperidone. Both medications are used to reduce irritability but have short-term and long-term side effects. This double-blind randomized placebo-controlled study will test the efficacy and safety of a new investigational product, cannabidivarin (CBDV), to address irritability and other core symptoms for children with autism ages 5-18. CBDV is non-psychoactive, is derived from the cannabis plant, but has different mechanisms of action to THC.
Document Details
- Document Type
- Technical Report
- Publication Date
- Nov 01, 2023
- Accession Number
- AD1227412
Entities
People
- Eric Hollander
Organizations
- Albert Einstein College of Medicine